Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.

He, Yan-Ling and Ligueros-Saylan, Monica and Sunkara, Gangadhar and Sabo, Ronald and Zhao, Charlie and Wang, Yibin and Campestrini, Joelle and Pommier, Francoise and Dole, Kiran and Marion, Alan and Dole, William and Howard, Danny (2008) Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. Journal of Clinical Pharmacology, 48 (1). pp. 85-95. ISSN 0091-2700

Abstract

We conducted 3 open-label, multiple-dose, 3-period, randomized, crossover studies in healthy subjects to assess the potential pharmacokinetic interaction between vildagliptin, a novel dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes, and representatives of 3 commonly prescribed antihypertensive drug classes: (1) the calcium channel blocker, amlodipine; (2) the angiotensin receptor blocker, valsartan; and (3) the angiotensin-converting enzyme inhibitor, ramipril. Coadministration of vildagliptin 100 mg with amlodipine 5 mg, valsartan 320 mg, or ramipril 5 mg had no clinically significant effect on the pharmacokinetics of these drugs. The 90% confidence intervals of the geometric mean ratios for area under the plasma concentration-time curve from time zero to 24 hours (AUC0-24h) and maximum plasma concentration (Cmax) for vildagliptin, amlodipine, and ramipril (and its active metabolite, ramiprilat) were contained within the acceptance range for bioequivalence (0.80-1.25). Valsartan AUC0-24h and Cmax increased by 24% and 14%, respectively, following coadministration of vildagliptin, but this was not considered clinically significant. Vildagliptin was generally well tolerated when given alone or in combination with amlodipine, valsartan, or ramipril in healthy subjects at steady state. No adjustment in dosage based on pharmacokinetic considerations is required should vildagliptin be coadministered with amlodipine, valsartan, or ramipril in patients with type 2 diabetes and hypertension.

Item Type: Article
Related URLs:
Additional Information: author can archive post-print (ie final draft post-refereeing); Publisher's version/PDF cannot be used
Keywords: Dipeptidyl peptidase IV inhibitor • angiotensin converting enzyme inhibitor • angiotensin receptor blocker • calcium channel blocker • pharmacokinetics • type 2 diabetes • vildagliptin
Related URLs:
Date Deposited: 14 Dec 2009 14:01
Last Modified: 31 Jan 2013 01:19
URI: https://oak.novartis.com/id/eprint/349

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.